ArticleBMC anesthesiology2025
Effects of dexmedetomidine and sevoflurane on optic nerve sheath diameter and postoperative nausea and vomiting in patients undergoing microvascular decompression: a retrospective cohort study.
Article in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundObserve the effects of dexmedetomidine(Dex) and sevoflurane(Sev) on the optic nerve sheath diameter(ONSD) in patients undergoing microvascular decompression (MVD). Find the most appropriate anesthetic maintenance medication scheme to reduce intracranial pressure (ICP)fluctuation and reduce the incidence of adverse reactions such as postoperative nausea and vomiting(PONV).
methodsIn this retrospective cohort study, 90 patients undergoing elective MVD surgery were allocated into Groups P, D, and S. Maintenance of anaesthesia: Group P propofol(Propo) 4-12mg/(kg.h) + remifentanil 0.1-0.2ug/(kg.min); Group D Dex 0.4ug/(kg. h) + Propo 4-12mg/(kg.h) + remifentanil 0.1-0.2ug/(kg.min); Group S 1-2% Sev + Propo 4-12mg/(kg.h) + remifentanil 0.1-0.2ug/(kg.min). The changes in ultrasound-measured ONSD relative to baseline and the occurrence of PONV at different time periods under different anaesthetic maintenance regimens were compared.
results(1) ONSD values increased significantly from T1 (10 min after tracheal intubation) to T6 (on leaving the post-anaesthesia care unit (PACU)), compared with the same group at T0 (5 min before anaesthesia). ONSD values at each time point of T1-T6, were the lowest in the Group D and the highest in the Group S.(2)In this study, the incidence of PONV within 24 h after MVD was 38.9%, with the lowest in Group D and the highest in Group S. (3) T2 (10 min after lying on side in forward neck flexion)ONSD, T6 (on leaving the PACU)ONSD, the usage of Sev and Dex were associated with PONV, whereas the usage of 0.4ug/(kg.h) Dex was a protective factor.
conclusionsDex has a lower effect on ONSD of MVD during the perioperative phase than Sev, and it can, to a certain extent, reduce the fluctuation of ICP. Dex lowers the incidence of PONV within 24 h after MVD and acts as a protective factor for PONV.
trial registrationThe protocol of this study was registered at www.chictr.org.cn (07/02/2024,ChiCTR MR-50-24-010856).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.